Skin Disorders

Acne is the most common skin disorder in the United States, affecting up to 50 million people, according to the American Academy of Dermatology. It's so widespread that by their mid-teens, more than...

- Additional End-of-Phase 2 Meeting Not Required- -Company to Submit for Special Protocol Assessment- KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received guidance...

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23, 2012 at 8:30 am Eastern Time....

ROCKVILLE, Md. -- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing oncology and CNS therapeutics, today provided guidance on its key pipeline, scientific and business goals for 2012. "Rexahn...

KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that Craig Dees, Ph.D., CEO, will present at BOCEMb: Noble Financial Capital Markets' Eighth Annual...

KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action of PV-10 will be presented at the...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/8f5a37/dermatology_therap) has announced the addition of the "Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and...

EWING, N.J. -- Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed exclusively its Oxybutynin Gel 3% to Daewoong Pharmaceuticals Co. Ltd.,for marketing in South Korea. Antares will receive undisclosed...

HEADNOTE HEALTHCARE: Shareholder offer could be "destabilizing" Irvine-based eye drug maker lsta Pharmaceuticals Inc. has fired a warning shot and hired an investment bank to pursue options in the wake of its rejection...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/ad208b/lip_and_oral_cavit) has announced the addition of GlobalData's new report "Lip and Oral Cavity Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. GlobalData, the industry...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/c7e9f8/hong_kong_pharmace) has announced the addition of the "Hong Kong Pharmaceuticals and Healthcare Report Q1 2012" report to their offering. Hong Kong continues to be viewed as a moderately...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/27d1e4/eczema_therapeutic) has announced the addition of GlobalData 's new report "Eczema Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. GlobalData, the industry analysis specialist,...

Not had time to read the journals? Let Dr Louise Newson bring you up to date on the latest research. - Bisphosphonates may be beneficial before knee and hip replacements BMJ 2011; 343:...

NECROBIOSIS LIPOIDICA Aetiology - A rare skin condition in which there is collagen degeneration with granulomatous response, thickened blood vessels and deposition of fat. - Cause unknown but more often occurs in, or...

TAMPA, Fla. & MINNEAPOLIS -- Biovest International, Inc. (OTCQB: "BVTI"), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI"), today announced that an article published by 'MyHealthNewsDaily' was featured on the Fox News...

BIOGGIO, Switzerland -- Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised 7.5 Million CHF from existing investors...

Four Patents Continue the Expansion of Company's Industry Leading Peptide Portfolio BOTHELL, Wash. -- Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that it has been granted four new...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/5fb90b/endpoints_clinic) has announced the addition of the "Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials"...

BENGALURU, India & SAN FRANCISCO -- Biocon (BSE:532523) (NSE:BIOCON) (ISIN:INE376G01013), Asia's premier biotechnology Company, today announced positive results from its Double Blind, Placebo Controlled, Phase 3, TREAT-PLAQ Study with Itolizumab in chronic plaque...